Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  de Morrée, Antoine ^a   Hensbergen, Paul J ^a   van Haagen, Herman H H B M ^a   Dragan, Irina ^a   Deelder, André M ^a   't Hoen, Peter A C ^a   Frants, Rune R ^a   van der Maarel, Silv̀ere M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYSFERLIN; MEMBRANE PROTEIN; MYOFERLIN; UNCLASSIFIED DRUG; VINCULIN; DYSF PROTEIN, MOUSE; MUSCLE PROTEIN; MYOFERLIN PROTEIN, MOUSE; PROTEOME;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; FOCAL ADHESION; FUNCTIONAL PROTEOMICS; MASS SPECTROMETRY; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PHAGOCYTOSIS; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SARCOLEMMA; SKELETAL MUSCLE; ANIMAL; CELL CULTURE; CLUSTER ANALYSIS; CYTOLOGY; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOPRECIPITATION; METABOLISM; METHODOLOGY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEOMICS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOBLASTS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEOME; PROTEOMICS; SARCOLEMMA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 78149474457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013854     Document Type: Article

References (64)

1. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, et al. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8: 855-861. ddc087 [pii].
2. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, et al. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168-172. 10.1038/nature01573 [doi];nature01573 [pii].
3. Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, et al. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20: 37-42. 10.1038/1689[doi].
4. Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, et al. (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49: 130-134.
5. Liu J, Aoki M, Illa I, Wu C, Fardeau M, et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31-36. 10.1038/1682 [doi].
6. Roche JA, Lovering RM, Bloch RJ (2008) Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. Neuroreport 19: 1579-1584. 10.1097/WNR.0b013e328311ca35 [doi].
7. Therrien C, Di Fulvio S, Pickles S, Sinnreich M (2009) Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 48: 2377-2384. 10.1021/bi802242r [doi].
8. Huang Y, Laval SH, van Remoortere A, Baudier J, Benaud C, et al. (2007) AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 21: 732-742. fj.06-6628com [pii];10.1096/fj.06-6628com [doi].
9. Patel P, Harris R, Geddes SM, Strehle EM, Watson JD, et al. (2008) Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2b. J Mol Biol 379: 981-990. S0022-2836(08)00492-0[pii];10.1016/j.jmb.2008.04.046 [doi].
10. Washington NL, Ward S (2006) FER-1 regulates Ca2+ -mediated membrane fusion during C. elegans spermatogenesis. J Cell Sci 119: 2552-2562. jcs.02980[pii];10.1242/jcs.02980 [doi].
11. Krajacic P, Hermanowski J, Lozynska O, Khurana TS, Lamitina T (2009) C. elegans dysferlin homolog fer-1 is expressed in muscle, and fer-1 mutations initiate altered gene expression of muscle enriched genes. Physiol Genomics 40: 8-14. 00106.2009 [pii];10.1152/physiolgenomics.00106.2009 [doi].
12. Yasunaga S, Grati M, Cohen-Salmon M, El-Amraoui A, Mustapha M, et al. (1999) A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet 21: 363-369. 10.1038/7693 [doi].
13. Roux I, Safieddine S, Nouvian R, Grati M, Simmler MC, et al. (2006) Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell 127: 277-289. S0092-8674(06)01218-9 [pii];10.1016/ j.cell.2006.08.040 [doi].
14. Yasunaga S, Grati M, Chardenoux S, Smith TN, Friedman TB, et al. (2000) OTOF encodes multiple long and short isoforms: genetic evidence that the long ones underlie recessive deafness DFNB9. Am J Hum Genet 67: 591-600. S0002-9297(07)63246-7 [pii];10.1086/303049 [doi].
15. Davis DB, Delmonte AJ, Ly CT, McNally EM (2000) Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet 9: 217-226. ddd030 [pii].
16. Doherty KR, Cave A, Davis DB, Delmonte AJ, Posey A, et al. (2005) Normal myoblast fusion requires myoferlin. Development 132: 5565-5575. dev.02155[pii];10.1242/dev.02155 [doi].
17. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, et al. (2009) MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 11: 56-64. ncb1812 [pii];10.1038/ncb1812 [doi].
18. Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, et al. (2009) Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 284: 15894-15902. M109.009589[pii];10.1074/jbc.M109.009589 [doi].
19. Hernandez-Deviez DJ, Martin S, Laval SH, Lo HP, Cooper ST, et al. (2006) Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 15: 129-142. ddi434 [pii];10.1093/ hmg/ddi434 [doi].
20. Hernandez-Deviez DJ, Howes MT, Laval SH, Bushby K, Hancock JF, et al. (2008) Caveolin regulates endocytosis of the muscle repair protein, dysferlin. J Biol Chem 283: 6476-6488. M708776200 [pii];10.1074/jbc.M708776200[doi].
21. Lennon NJ, Kho A, Bacskai BJ, Perlmutter SL, Hyman BT, et al. (2003) Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal woundhealing. J Biol Chem 278: 50466-50473. 10.1074/jbc.M307247200[doi];M307247200 [pii].
22. McNeil AK, Rescher U, Gerke V, McNeil PL (2006) Requirement for annexin A1 in plasma membrane repair. J Biol Chem 281: 35202-35207. M606406200[pii];10.1074/jbc.M606406200 [doi].
23. Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, et al. (2005) Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet 13: 721-730. 5201414[pii];10.1038/sj.ejhg.5201414 [doi].
24. Huang Y, de Morree A, van Remoortere A, Bushby K, Frants RR, et al. (2008) Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 17: 1855-1866. ddn081 [pii];10.1093/hmg/ddn081 [doi].
25. Beckmann JS, Spencer M (2008) Calpain 3, the ''gatekeeper'' of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 18: 913-921. S0960-8966(08)00618-4 [pii];10.1016/j.nmd.2008.08.005 [doi].
26. Mellgren RL, Zhang W, Miyake K, McNeil PL (2007) Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane. J Biol Chem 282: 2567-2575. M604560200 [pii];10.1074/jbc.M604560200 [doi].
27. Mellgren RL, Miyake K, Kramerova I, Spencer MJ, Bourg N, et al. (2009) Calcium-dependent plasma membrane repair requires m- or mu-calpain, but not calpain-3, the proteasome, or caspases. Biochim Biophys Acta 1793: 1886-1893. S0167-4889(09)00238-9 [pii];10.1016/j.bbamcr.2009.09.013 [doi].
28. Borgonovo B, Cocucci E, Racchetti G, Podini P, Bachi A, et al. (2002) Regulated exocytosis: a novel, widely expressed system. Nat Cell Biol 4: 955-962. 10.1038/ncb888 [doi];ncb888 [pii].
29. Cocucci E, Racchetti G, Podini P, Meldolesi J (2007) Enlargeosome traffic: exocytosis triggered by various signals is followed by endocytosis, membrane shedding or both. Traffic 8: 742-757. TRA566 [pii];10.1111/j.1600-0854.2007.00566.x [doi].
30. Lorusso A, Covino C, Priori G, Bachi A, Meldolesi J, et al. (2006) Annexin2 coating the surface of enlargeosomes is needed for their regulated exocytosis. EMBO J 25: 5443-5456. 7601419 [pii];10.1038/sj.emboj.7601419 [doi].
31. Chiu YH, Hornsey MA, Klinge L, Jorgensen LH, Laval SH, et al. (2009) Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 18: 1976-1989. ddp121 [pii];10.1093/hmg/ddp121 [doi].
32. De Luna N, Gallardo E, Sonnet C, Chazaud B, Dominguez-Perles R, et al. (2010) Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J Neuropathol Exp Neurol 69: 643-653. 10.1097/NEN.0- b013e3181e0d01c [doi].
33. Klinge L, Laval S, Keers S, Haldane F, Straub V, et al. (2007) From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 21: 1768-1776. fj.06-7659com [pii];10.1096/fj.06-7659com [doi].
34. Covian-Nares JF, Koushik SV, Puhl HLI, Vogel SS (2010) Membrane wounding triggers ATP release and dysferlin-mediated intercellular calcium signaling. J Cell Sci 123: 1884-1893. jcs.066084 [pii];10.1242/jcs.066084 [doi].
35. Izzedine H, Brocheriou I, Eymard B, Le Charpentier M, Romero NB, et al. (2006) Loss of podocyte dysferlin expression is associated with minimal change nephropathy. Am J Kidney Dis 48: 143-150. S0272-6386(06)00766-9[pii];10.1053/j.ajkd.2006.04.074 [doi].
36. Luft FC (2007) Dysferlin, dystrophy, and dilatative cardiomyopathy. J Mol Med 85: 1157-1159. 10.1007/s00109-007-0252-8 [doi].
37. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, et al. (2001) The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 10: 1761-1766.
38. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, et al. (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162: 486-498.
39. Foxton RM, Laval SH, Bushby KM (2004) Characterisation of the dysferlin skeletal muscle promoter. Eur J Hum Genet 12: 127-131. 10.1038/ sj.ejhg.5201092 [doi];5201092 [pii].
40. Rutgers KS, van Remoortere A, van Buchem MA, Verrips CT, Greenberg SM, et al. (2009) Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging.
41. Azakir BA, Di Fulvio S, Therrien C, Sinnreich M (2010) Dysferlin interacts with tubulin and microtubules in mouse skeletal muscle. PLoS One 5: e10122. 10.1371/journal.pone.0010122 [doi].
42. Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, et al. (2005) Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol 64: 334-340.
43. Ampong BN, Imamura M, Matsumiya T, Yoshida M, Takeda S (2005) Intracellular localization of dysferlin and its association with the dihydropyridine receptor. Acta Myol 24: 134-144.
44. Jelier R, Schuemie MJ, Roes PJ, van Mulligen EM, Kors JA (2008) Literaturebased concept profiles for gene annotation: the issue of weighting. Int J Med Inform 77: 354-362.
45. Pramono ZA, Lai PS, Tan CL, Takeda S, Yee WC (2006) Identification and characterization of a novel human dysferlin transcript: dysferlin_v1. Hum Genet 120: 410-419. 10.1007/s00439-006-0230-1 [doi].
46. Nagaraju K, Rawat R, Veszelovszky E, Thapliyal R, Kesari A, et al. (2008) Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172: 774-785. ajpath.2008.070327 [pii];10.2353/ajpath.2008.070327 [doi].
47. De Luna N, Freixas A, Gallano P, Caselles L, Rojas-Garcia R, et al. (2007) Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 17: 69-76. S0960-8966(06)00538-4 [pii];10.1016/j.nmd.2006.09.006 [doi].
48. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, et al. (2002) A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 51: 129-133. 10.1002/ana.10080 [pii].
49. Wein N, Krahn M, Courrier S, Bartoli M, Salort-Campana E, et al. (2010) Immunolabelling and flow cytometry as new tools to explore dysferlinopathies. Neuromuscul Disord 20: 57-60. S0960-8966(09)00584-7 [pii];10.1016/ j.nmd.2009.08.004 [doi].
50. Bushby K (2009) Diagnosis and management of the limb girdle muscular dystrophies. Pract Neurol 9: 314-323. 9/6/314 [pii];10.1136/jnnp.2009.193938[doi].
51. Munoz P, Rosemblatt M, Testar X, Palacin M, Zorzano A (1995) Isolation and characterization of distinct domains of sarcolemma and T-tubules from rat skeletal muscle. Biochem J 307 (Pt 1): 273-280.
52. Yamaji S, Suzuki A, Kanamori H, Mishima W, Yoshimi R, et al. (2004) Affixin interacts with alpha-actinin and mediates integrin signaling for reorganization of F-actin induced by initial cell-substrate interaction. J Cell Biol 165: 539-551. 10.1083/jcb.200308141 [doi];jcb.200308141 [pii].
53. Matsuda C, Kameyama K, Suzuki A, Mishima W, Yamaji S, et al. (2008) Affixin activates Rac1 via betaPIX in C2C12 myoblast. FEBS Lett 582: 1189-1196. S0014-5793(08)00168-3 [pii];10.1016/j.febslet.2008.01.064 [doi].
54. Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating MT, et al. (2002) Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 105: 431-437.
55. Impagliazzo A, Tepper AW, Verrips TC, Ubbink M, van der Maarel SM (2010) Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD. FEBS Lett 584: 1558-1564. S0014-5793(10)00204-8 [pii];10.1016/ j.febslet.2010.03.010 [doi].
56. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, et al. (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75-79.
57. Wenzel K, Carl M, Perrot A, Zabojszcza J, Assadi M, et al. (2006) Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum Mutat 27: 599-600. 10.1002/ humu.9424 [doi].
58. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, et al. (2007) Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/ lysosome ERAD(II). Hum Mol Genet 16: 618-629. ddm002 [pii];10.1093/ hmg/ddm002 [doi].
59. Hayashi YK, Chou FL, Engvall E, Ogawa M, Matsuda C, et al. (1998) Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 19: 94-97.
60. Disatnik MH, Rando TA (1999) Integrin-mediated muscle cell spreading. The role of protein kinase c in outside-in and inside-out signaling and evidence of integrin cross-talk. J Biol Chem 274: 32486-32492.
61. Quach NL, Rando TA (2006) Focal adhesion kinase is essential for costamerogenesis in cultured skeletal muscle cells. Dev Biol 293: 38-52.
62. Quach NL, Biressi S, Reichardt LF, Keller C, Rando TA (2009) Focal adhesion kinase signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential for normal myoblast fusion. Mol Biol Cell 20: 3422-3435. E09-02-0175[pii];10.1091/mbc.E09-02-0175 [doi].
63. Collinet C, Stoter M, Bradshaw CR, Samusik N, Rink JC, et al. (2010) Systems survey of endocytosis by multiparametric image analysis. Nature 464: 243-249.
64. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, et al. (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272. M500061-MCP200 [pii];10.1074/ mcp.M500061-MCP200 [doi].